Skip to main content
  • Login
  • Contact
  • Subscriptions

Search form

Home

Deer Park Tribune

Deer Park weather

  • Home
  • News
  • Sports
  • Obituaries
  • Entertainment
    • Special Sections
    • Talking About...
  • Photos
  • Videos
  • Classifieds
    • Classified Display Ads
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akari Therapeutics (NQ: AKTX )

2.180 USD -0.090 (-3.96%)
Streaming Delayed Price Updated: 7:01 AM EDT, Apr 13, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,663
Open 2.270
Bid (Size) 2.180 (6)
Ask (Size) 2.200 (10)
Prev. Close 2.270
Today's Range 2.100 - 2.270
52wk Range 1.420 - 4.210
Shares Outstanding 15,256,933
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
April 12, 2021
From GlobeNewswire News Releases
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
March 04, 2021
Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma 
From GlobeNewswire News Releases

Performance

YTD
+20.44%
+20.44%
1 Month
-31.66%
-31.66%
3 Month
+5.83%
+5.83%
6 Month
+19.78%
+19.78%
1 Year
+40.65%
+40.65%

More News

Read More
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
February 25, 2021
From GlobeNewswire News Releases
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
February 01, 2021
From GlobeNewswire News Releases
Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan
April 12, 2021
Tags Phase 3 Trial Biotech General
From Benzinga
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
January 06, 2021
From GlobeNewswire News Releases
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
December 11, 2020
From GlobeNewswire News Releases
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 05, 2021
Tags XTLB NVIV EVFM
From Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 04, 2021
Tags ACOR SLRX Market News
From Benzinga
Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
February 25, 2021
Tags FDA Biotech Market News
From Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
February 22, 2021
Tags General BNGO ADIL
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2020 The Deer Park Tribune | 104 N. Main Street | Deer Park, WA 99006 | (509) 276-5043
All property rights for the entire contents of this publication shall be the property of The Deer Park Tribune.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media